Blog Posts

C. Jillian Tsai: Phase II Study of Pembrolizumab and Chemoradiation in Head and Neck Cancer

C. Jillian Tsai/X

May 30, 2025, 05:52

C. Jillian Tsai: Phase II Study of Pembrolizumab and Chemoradiation in Head and Neck Cancer

C. Jillian Tsai, Lead of Palliative Radiotherapy and Oligometastases Program (PROP) at Princess Margaret Cancer Centre, posted on X:

“Remarkable efforts to obtain on-treatment tissue to study TME.

CRT with sequential pembro *might* be more favorable than concurrent pembro.”

Ttile: Randomized Phase II Study of Concurrent Versus Sequential Pembrolizumab in Combination With Chemoradiation in Locally Advanced Head and Neck Cancer

Authors: Dan P. Zandberg, Lazar Vujanovic, David A. Clump, Brian P. Isett, Hong Wang, Gabriel Sica, Riyue Bao, Housayin Li, James Ohr, Heath D. Skinner, Raja R. Seethala, Simion I. Chiosea, Robert L. Ferris, Julie E. Bauman

Read The Full Article at Journal of Clinical Oncology.

C. Jillian Tsai: Phase II Study of Pembrolizumab and Chemoradiation in Head and Neck Cancer

More posts featuring Head and Neck Cancer.

Brian P. Isett C. Jillian Tsai cancer Dan P. Zandberg David A. Clump Gabriel Sica Heath D. Skinner Hong Wang Housayin Li James Ohr Julie E. Bauman Lazar Vujanovic OncoDaily Oncology Raja R. Seethala Riyue Bao Robert L. Ferris Simion I. Chiosea

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Writer?

LOCKTAC Molecular Glues Are Changing the Rules of Drug Discovery - Amgen

Top 10 Immunotherapy Trials in Lung Cancer to Watch at ESMO 2025

FDA has Granted Full Market Approval for Papzimeos - NIH

Kirsty Duncan։ Thirty-two Months Into Fighting Cancer...